DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LANOXIN PEDIATRIC

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lanoxin Pediatric

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00578617	Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial	Completed	Duke Clinical Research Institute	N/A	2006-09-01	The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617	Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial	Completed	St. Jude Medical	N/A	2006-09-01	The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617	Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial	Completed	Mayo Clinic	N/A	2006-09-01	The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00831506	Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects	Completed	Medivation, Inc.	Phase 1	2009-02-01	This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA.

Clinical Trial Conditions for Lanoxin Pediatric

Condition Name

Condition Name for Lanoxin Pediatric
Intervention	Trials
Healthy	4
Adenocarcinoma of the Pancreas	1
Huntington Disease	1
Diabetes	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lanoxin Pediatric
Intervention	Trials
Pancreatic Neoplasms	1
Adenocarcinoma	1
Melanoma	1
Huntington Disease	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lanoxin Pediatric

Trials by Country

Trials by Country for Lanoxin Pediatric
Location	Trials
United States	14
Belgium	1
Sweden	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lanoxin Pediatric
Location	Trials
Texas	2
California	2
Connecticut	1
Utah	1
Pennsylvania	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lanoxin Pediatric

Clinical Trial Phase

Clinical Trial Phase for Lanoxin Pediatric
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	6
N/A	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lanoxin Pediatric
Clinical Trial Phase	Trials
Completed	6
Not yet recruiting	2
Recruiting	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lanoxin Pediatric

Sponsor Name

Sponsor Name for Lanoxin Pediatric
Sponsor	Trials
Society of Family Planning	1
National Cancer Institute (NCI)	1
Pfizer	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lanoxin Pediatric
Sponsor	Trials
Industry	8
Other	6
NIH	1

Export unavailable in trial.
Subscribe for complete access.